Most Popular in the Last...

Home

drug discovery

See the following -

OSDD Starts Youtube Competition For TB

Staff Writer | BioSpectrum | November 2, 2012

India's Open Source Drug Discovery initiative and Vigyan Prasar have called for videos based on the theme, 'The need for TB drugs'. Participants need to be at least 18 years of age and can either upload the video on Youtube or send the video as an email attachment to the authorities, before Nov 26 Read More »

Patient Engagement, Data Liberation And Portability

Christine Årdal and John-Arne Røttingen | PLOS Neglected Tropical Diseases | September 20, 2012

Open source drug discovery can be an influential model for discovering and developing new medicines and diagnostics for neglected diseases. It offers the opportunity to accelerate the discovery progress while keeping expenditures to a minimum by encouraging incremental contributions from volunteer scientists.
Read More »

Pharma Not So Big On Cloud For Clinical Trials

Chris Anderson | Government Health IT | December 26, 2012

Big pharma is notoriously slow-footed when it comes to changing its business model. Some would argue it is a major reason why so many pharmaceutical companies are struggling as their blockbuster drugs go off patent. In short, there is an institutionalized caution to embracing the kind of change moving to the cloud presents.

Read More »

Pistoia Alliance Driving Open Innovation in Bioresearch

By Roger A. Maduro | July 9, 2014

The Pistoia Alliance recently held its 4th Annual Conference at the Marriott Marquis in New York City. As part of the Next Chapter Initiative this was widened to a three-day event to include a special members-only meeting on the second day, kindly hosted by Thomson Reuters at their headquarters in Times Square, and a face-to-face board meeting hosted by Roche at the Alexandria Centre. Read More »

Pistoia Alliance Wins Bio-IT World Grand Prize-Continues Innovation Mission

I received an email newsletter this morning from the Pistoia Alliance and it was so full of information and updates that I decided to post the entire newsletter as an article. A note on the Pistoia Alliance is long overdue. I had meant to write an article on the Alliance back in April after the 2014 Bio-IT World conference organizers announced that Pistoia's HELM project had been chosen as one of the Grand prize winners. Read More »

Posted July 9, 2014 - 9:56pm by Roger A. Maduro

Recent Trends in Collaborative, Open Source Drug Discovery

Anuradha Roy, Peter R. McDonald and Rathnam Chaguturu | The Open Conference Proceedings Journal | October 30, 2011

In order to be more profitable and productive, the pharmaceutical industry has embraced an open innovation approach to share the drug discovery processes and data with academia.

Read More »

Recursion Releases Open Source Data from Largest Ever Dataset of Biological Images, Inviting Data Science Community to Develop New and Improved Machine Learning Algorithms for the Life Sciences Industry

Press Release | Recursion | May 6, 2019

Recursion, a Fast Company "Most Innovative Company" and leader in the artificial intelligence for drug discovery movement, today announced it will open-source a glimpse of the massive biological dataset the company has been building for more than five years. At more than two petabytes, and across more than 10 million different biological contexts, Recursion's data is the world's largest image-based dataset designed specifically for the development of machine learning algorithms in experimental biology and drug discovery.

Read More »

TB or Not TB: India Crowdsources Research

Jason Overdorf | GlobalPost | July 11, 2012

Facing nearly 2 million new tuberculosis cases every year — more and more of them drug-resistant — India has a bigger stake in finding a better treatment for TB than any other country. Read More »

The Holy Grail Of New Drug Development

Rishikesha T. Krishnan | The Hindu Business Line | July 4, 2013

The announcement by Zydus Cadila in early June that their new drug to treat diabetics who also suffer from high cholesterol has passed all stages of clinical trials is an important landmark for the Indian pharmaceutical industry. [...] Read More »

The Ontario Institute for Cancer Research and the Structural Genomics Consortium develop and give away new drug-like molecule to help crowd-source cancer research.

Press Release | Ontario Institute for Cancer Research, Structural Genomics Consortium | September 3, 2015

Through a novel open source approach the molecule has been made freely available to the cancer research community to help discover new therapeutic strategies for cancer patients sooner...Researchers from the Ontario Institute for Cancer Research (OICR) and the Structural Genomics Consortium (SGC) at the MaRS Discovery District in Toronto have developed a new drug prototype called OICR-9429 and made it freely available to the research community. Already research conducted by international groups using OICR-9429 has shown it to be effective in stopping cancer cell growth in breast cancer cell lines and a specific subtype of leukemia cells.

Read More »

The Second Global Innovation Roundtable Sets The Agenda For Global Cooperation In Innovation [India]

Staff Writer | India Education Diary | November 3, 2012

The National Innovation Council (NInC), chaired by Mr Sam Pitroda, Adviser to the Prime Minister, hosted the second Global Innovation Roundtable (GIR) on 1st and 2nd November 2012 in New Delhi, India. Read More »

To Err Is Human, To Diagnose Artificial Intelligence is...?

By Kim Bellard | September 5, 2016

A new study found that physicians have a surprisingly poor knowledge of the benefits and harms of common medical treatments.  Almost 80% overestimated the benefits, and two-thirds overestimated the harms.  And, as Aaron Carroll pointed out, it's not just that they were off, but "it's how off they often were." Anyone out there who still doesn't think artificial intelligence (AI) is needed in health care? The authors noted that previous studies have found that patients often overestimate benefits as well, but tended to minimize potential harms.  Not only do physicians overestimate harm, they "underestimate how often most treatments have no effects on patients -- either harmful or beneficial"...

Read More »

We Cannot Do Modern Science Unless It's Open

By Peter Murray-Rust | August 16, 2014

Open is about sharing and collaboration. It's the idea that "we" is more powerful, more rewarding and fulfilling than "I". I can't promise jobs, but I do know that open is becoming very big. Governments and funders are pushing the open agenda, even though academics are generally uninterested or seriously self-interested... Read More »

Why Open Drug Discovery Needs Four Simple Rules For Licensing Data And Models

Antony J. Williams, John Wilbanks, and Sean Ekins | PLoS Computational Biology | September 27, 2012

As we see a future of increased database integration, the licensing of the data may be a hurdle that hampers progress and usability. We have formulated four rules for licensing data for open drug discovery, which we propose as a starting point for consideration by databases and for their ultimate adoption. Read More »